Special Issue "Botulinum Toxin in the Management of Children with Cerebral Palsy"
Deadline for manuscript submissions: 31 January 2022.
Botulinum toxin A (BTX) is an established treatment modality for children with cerebral palsy (CP) for the management of hypertonia. It has been demonstrated to be effective, especially as part of a multimodal integrated management. Goals are typically contracture prevention and comfort in non-ambulatory patients and improvement of function and motor and gait development in children GMFCS I-III. Goals should be set for each individual child, taking into account long-term management, including other spasticity treatment modalities and orthopedic procedures that might be necessary.
Nevertheless, there is still a lack of a uniform BTX treatment strategy, especially regarding guidelines such as optimal indications regarding ages and goals and pre-and post-injection treatment. Further, outcomes have not been studied extensively on all ICF outcome domains, but mostly on body structure and function. Finally, there are concerns about the long-term effects of the toxin on the muscle morphology in the already abnormal CP muscle and concerns about possible long-term multiple repeat injections in children already demonstrating contractures and orthopedic structural abnormalities.
As a leading expert in your field, we would like you to participate in expanding the knowledge regarding the use of BTX in children with CP by submitting your research.
Prof. Dr. Anja Van Campenhout
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Toxins is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- cerebral palsy
- botulinum toxin
- spasticity management
- muscle morphology